- Home
- MGNX vs LITS Comparison
MGNX vs LITS Comparison
Compare MGNX & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGNX | LITS |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9M | 96.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGNX | LITS |
|---|---|---|
| Price | $1.43 | $1.73 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.20 | N/A |
| AVG Volume (30 Days) | ★ 907.4K | 497.9K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $127,626,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $1.46 |
| 52 Week High | $3.68 | $9.00 |
Technical Indicators
Market Signals| Indicator | MGNX | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | N/A |
| Support Level | $1.33 | N/A |
| Resistance Level | $1.55 | N/A |
| Average True Range (ATR) | 0.10 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 9.82 | 0.00 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.